[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data…
[ad_1] A woman using an inhaler. BSIP | Universal Images Group | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Inhalers will soon get a whole lot cheaper for some Americans. Three of the world’s largest inhaler makers have agreed to cap…
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but…
[ad_1] The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman…
[ad_1] Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion,…
[ad_1] Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year…
[ad_1] A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes thousands of hospitalizations and…
[ad_1] Artur Widak | Nurphoto | Getty Images Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study. The biotech company hopes its shot, mRNA-1083, can win approval…
[ad_1] Pharmacist Ani Martirosyan administers an immunization to a patient at a CVS on Tuesday, Sept. 12, 2023 in Glendale, CA. Brian Van Der Brug | Los Angeles Times | Getty Images For the first time ever, vaccines for Covid, the flu and respiratory syncytial virus are available in the U.S. Public health officials are…
[ad_1] A nurse prepares a flu shot at Huntington Village Pediatrics, in Huntington, New York on December 8, 2021. Steve Pfost | Newsday | Getty Images Moderna on Wednesday said its experimental mRNA-based flu vaccine produced a stronger immune response against four strains of the virus than a currently available flu vaccine in a late-stage…
